BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, February 23, 2026
Home » Authors » Tamra Sami

Articles by Tamra Sami

Sienna Cancer Diagnostics expands footprint to Asia as it looks to expand pipeline

Jan. 28, 2019
By Tamra Sami

Australia's Neuclone poised to disrupt pharma market with broad pipeline of biosimilars

Jan. 28, 2019
By Tamra Sami
PERTH, Australia – Australia's Neuclone Pharmaceuticals Ltd. is developing a broad pipeline of biosimilars, and it plans on being a big disrupter to the global pharma market.
Read More

Australia gears up to implement formal GCP inspections program

Jan. 24, 2019
By Tamra Sami

Australia gears up to implement formal GCP inspections program

Jan. 24, 2019
By Tamra Sami
PERTH, Australia – Australia's Therapeutic Goods Administration (TGA) is launching a pilot good clinical practices (GCP) program in the hopes of launching a routine GCP inspections program.
Read More

Australia's Invion to enter clinic with photosensitizer drug to treat melanoma

Jan. 23, 2019
By Tamra Sami
PERTH, Australia – Like many Aussie companies, Invion Ltd. started out with some assets that it had a difficult time progressing forward, and it ended up remaking itself into a completely different company with new assets. Now, Melbourne-headquartered Invion plans to enter the clinic early this year with a photosensitizer therapy to treat melanoma.
Read More

Australia's Invion to enter clinic with photosensitizer drug to treat melanoma

Jan. 23, 2019
By Tamra Sami
PERTH, Australia – Like many Aussie companies, Invion Ltd. started out with some assets that it had a difficult time progressing forward, and it ended up remaking itself into a completely different company with new assets. Now, Melbourne-headquartered Invion plans to enter the clinic early this year with a photosensitizer therapy to treat melanoma.
Read More

Oncores develops hand-held imaging tool to help surgeons remove cancerous tissue

Jan. 22, 2019
By Tamra Sami

New Zealand prepares major overhaul of drug, device regs

Jan. 16, 2019
By Tamra Sami

New Zealand prepares major overhaul of drug, device regs

Jan. 16, 2019
By Tamra Sami
PERTH, Australia – After nearly 40 years, New Zealand is preparing new legislation to regulate drugs and devices that would replace the Medicines Act 1981.
Read More

Neuroscientist discovers new region of the brain that likely controls fine motor skills

Jan. 15, 2019
By Tamra Sami
Previous 1 2 … 188 189 190 191 192 193 194 195 196 … 224 225 Next

Popular Stories

  • Today's news in brief

    BioWorld
  • IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

    BioWorld Science
    Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
  • Illustration of head with maze that is missing parts

    Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

    BioWorld Science
    Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
  • Illustration of brain and antibodies

    VST Bio’s VB-001 is neuroprotector after stroke

    BioWorld Science
    At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...
  • Pill in immersive interface

    New mechanism of action identified for QC-6352

    BioWorld Science
    QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing